Details for Patent: 8,673,341

Which drugs does patent 8,673,341 protect, and when does it expire?

Patent 8,673,341 protects DURYSTA and is included in one NDA.

This patent has eighty-one patent family members in twenty-three countries.

Summary for Patent: 8,673,341

Title:	Intraocular pressure reduction with intracameral bimatoprost implants
Abstract:	The present invention provides a method of treating an ocular condition in an eye of a patient, comprising the step of placing a biodegradable intraocular implant in an eye of the patient, the implant comprising a prostamide and a biodegradable polymer matrix that releases drug at a rate effective to sustain release of an amount of the prostamide from the implant to provide an amount of the prostamide effective to prevent or reduce a symptom of an ocular condition of the eye, wherein said ocular condition is elevated IOP and said implant is placed in an intracameral location to dilate the outflow channels of the eye emanating from Schlemm's Canal.
Inventor(s):	Hughes; Patrick M. (Aliso Viejo, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	12/761,765
Patent Claim Types: see list of patent claims	Use; Device;

Drugs Protected by US Patent 8,673,341

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes						REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT

International Family Members for US Patent 8,673,341

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E397934
Australia	2005244203
Australia	2007223057
Australia	2011239642